Group 1: Retail and Service Industry Insights - The report highlights a recovery in the hotel and duty-free sectors, suggesting that the hotel prices have gradually increased since the second half of this year, with a recommendation to focus on hotel stocks such as Huazhu Group, Jinjiang Hotels, and ShouLai Hotels [6][12][17] - Duty-free sales are showing signs of bottoming out, with new policies implemented to expand the range of duty-free products and eligible consumers, leading to a significant increase in sales figures [12][15][16] - The report emphasizes the importance of service consumption policies, particularly in the context of the ice and snow economy, silver-haired economy, and sports events, recommending investments in companies like Changbai Mountain and Sanchuan Tourism [26][28][29] Group 2: AI Applications in Various Industries - The report discusses the acceleration of AI applications in the education and human resources sectors, with companies like Keri International and Beijing Renli leveraging AI to enhance recruitment efficiency [39][44] - AI's integration into 3D printing and e-commerce is highlighted, with a focus on companies like Huina Technology and Xiaogoods City, which are expected to benefit from cost reductions through full-chain penetration [6][39] - The report notes that AI applications are driving significant changes in operational efficiency and commercial opportunities across various sectors, particularly in human resources [39][44] Group 3: Beauty and Personal Care Sector - The beauty and personal care industry is experiencing a mild recovery, with domestic brands showing strong performance during the Double Eleven shopping festival, indicating a shift in competitive dynamics [6][32] - The report identifies key players in the beauty sector, recommending brands like Mao Ge Ping and Shanghai Jahwa, while also suggesting a focus on high-growth segments within the industry [6][32] - The medical beauty sector is under pressure but is seeing consolidation and innovation, with recommendations for companies like Jinbo Biological and Kedi-B [6][32] Group 4: Jewelry and Precious Metals - The jewelry sector is undergoing a transformation, with a focus on overseas expansion as a second growth curve, recommending companies like Laopu Gold and Chaohongji [6][32] - The report emphasizes the importance of high-value jewelry products and the impact of new tax regulations on the market dynamics [6][32] Group 5: Food and Beverage Industry - The food and beverage sector is witnessing a shift, with a focus on leading brands expanding their store counts and product categories, particularly in the tea and dining segments [32][38] - The report highlights the competitive landscape in the restaurant industry, noting the resilience of Western fast food and the growth of Chinese casual dining brands [32][38]

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - In November, the online apparel and accessories sector experienced a year-on-year growth of 9.1%, with an increase in growth rate compared to October. The average temperature in November was 4.2°C, which is 0.9°C higher than the historical average but 0.9°C lower than last year, indicating robust sales despite lower temperatures [2][11] - The outdoor segment continues to lead the industry with brands like Descente, Kelong, and Aon running year-on-year growth rates of 32.8%, 32.4%, and 21.4% respectively. In the home textile and menswear sectors, brands like Luolai Life and Bosideng saw year-on-year growth of 16.0% and 8.8% respectively [2][11] - The report highlights the approval of two animal collagen products by the National Medical Products Administration, marking significant advancements in concentration, implant materials, and indications [3][13] Industry Data Tracking - In October, apparel retail sales grew by 6.3% year-on-year, with the growth rate improving from September. This was attributed to seasonal promotions and a recovery in offline store traffic due to reduced extreme weather [4][19] - The cosmetics sector also showed resilience, with retail sales increasing by 9.6% year-on-year, reflecting a 11.6 percentage point increase from September [4][29] - The jewelry retail sector continued to recover, with a year-on-year growth of 9.6% in October, supported by rising gold prices and increased regional consumer enthusiasm [4][19] Investment Recommendations - For the apparel sector, Hai Lan Home is recommended for its innovative urban outlet expansion and strong profitability, while Li Ning is expected to see a turning point in 2025 [5][27] - In the beauty and personal care segment, recommendations include Juzi Biological for its strong data resilience and Jinbo Biological for its anticipated new product launches [5][31] - The gold and jewelry sector is recommended for brands with strong market presence, such as Laopu Gold, due to the favorable gold price trends [5][31]

www.hczq.com 证券研究报告 | 医药生物 | 2025年12月13日 华创医药投资观点&研究专题周周谈 · 第154期 2025Q3实体药店市场分析 本周专题联系人：高初蕾 华创医药团队： | 首席分析师 | 郑辰 | | 执业编号：S0360520110002 | 邮箱：zhengchen@hcyjs.com | | --- | --- | --- | --- | --- | | 联席首席分析师 | | 刘浩 | 执业编号：S0360520120002 | 邮箱：liuhao@hcyjs.com | | 医疗器械组组长 | | 李婵娟 | 执业编号：S0360520110004 | 邮箱：lichanjuan@hcyjs.com | | 中药和流通组组长 | | 高初蕾 | 执业编号：S0360524070002 | 邮箱：gaochulei@hcyjs.com | | 分析师 | 王宏雨 | | 执业编号：S0360523080006 | 邮箱：wanghongyu@hcyjs.com | | 分析师 | 朱珂琛 | | 执业编号：S0360524070007 | 邮箱：zhukechen@h ...

Market Overview - The overall sentiment in the pharmaceutical sector remains cautious, with the CITIC Pharmaceutical Index declining by 1.10%, underperforming the CSI 300 Index by 1.02 percentage points, ranking 15th among 30 primary sectors [9] - The retail scale of physical pharmacies in China for the first three quarters of 2025 reached CNY 449 billion, a year-on-year decline of 1.9%, with Q3 showing a cumulative scale of CNY 152.9 billion, down 1.4% year-on-year but up 3.0% quarter-on-quarter [21][15] Drug Market Analysis - The drug retail market in Q3 experienced a slight year-on-year decline, attributed to factors such as reduced incidence of respiratory diseases. The cumulative scale for the first three quarters was CNY 3,654 billion, down 0.8% year-on-year, with Q3 retail scale at CNY 1,241 billion, also down 0.8% year-on-year [28][23] - The sales growth rate for major drug categories showed a downward trend, with the largest decline seen in health products, exceeding 17%, while the smallest decline was in pharmaceuticals, slightly down by 1.2% [22] Traditional Chinese Medicine (TCM) Analysis - The cumulative scale of TCM retail in physical pharmacies for the first three quarters of 2025 was CNY 344 billion, down 4.4% year-on-year, with Q3 cumulative scale at CNY 117 billion, down 4.1% year-on-year [25] - Monthly retail scale for TCM showed fluctuations, with September seeing a significant month-on-month increase of 9.8%, indicating potential recovery [25] Medical Device Market Analysis - The medical device market showed signs of recovery in Q3, with a cumulative scale of CNY 210 billion for the first three quarters, down 1.9% year-on-year, and Q3 cumulative scale at CNY 73 billion, remaining stable year-on-year [35][29] - The market for high-value consumables, particularly in orthopedics, is expected to grow due to increased surgical volumes and domestic market consolidation following procurement policies [46] Health Products Market Analysis - The cumulative scale of health products in physical pharmacies for the first three quarters was CNY 171 billion, down 17.0% year-on-year, with Q3 cumulative scale at CNY 57 billion, down 13.6% year-on-year [32] - Monthly retail scale for health products showed a recovery trend in September, with a month-on-month increase of 22.2%, indicating a narrowing of the year-on-year decline [32] Investment Opportunities - The pharmaceutical sector is viewed as having low valuations, with public funds showing low allocation to the sector. The anticipated recovery in macroeconomic factors and the potential for significant growth in large categories are seen as positive indicators for the industry [13] - The innovation drug sector is expected to shift focus from quantity to quality, emphasizing differentiated products and internationalization, with recommendations to focus on companies that can deliver profits [13]

Core Insights - The article emphasizes that despite the prevailing narrative of economic hardship, certain industries are thriving and generating substantial profits, particularly in the context of Japan's "lost 30 years" and its implications for China [3][4]. Group 1: Emerging Opportunities - The article identifies eight key industries that are experiencing growth despite a low-desire society, highlighting that consumer demand is shifting rather than disappearing [4][5]. - The second-hand economy is booming, with examples like Japan's "Daikokuya" and China's "Hongbulin" and "Panghu" seeing significant revenue increases as consumers opt for second-hand luxury goods [6][7][8][9]. - The pet economy is flourishing, with brands like "Inaba" in Japan and "Guibao" in China witnessing strong sales, as younger generations prioritize spending on pets over traditional family structures [11][12][13][14][15]. Group 2: Health and Wellness Trends - The adult care market is expanding, with Japan's "Unicharm" leading the adult diaper segment, which has surpassed $10 billion in market size, indicating a potential growth area in China [16][17][18]. - Health food and beverage sectors are rising due to changing demographics and increased health awareness, with brands like "Oriental Leaf" and "Jianchun" gaining traction in the post-pandemic era [21][22]. Group 3: Beauty and Lifestyle - The beauty economy is thriving, with products like collagen supplements and home beauty devices achieving significant sales, reflecting a consumer desire for affordable beauty solutions [23][25]. - Outdoor and leisure activities are gaining popularity, with brands like "Snow Peak" in Japan and various Chinese outdoor brands experiencing rapid sales growth, as consumers seek experiences over material possessions [25][26][27]. Group 4: Emotional and Convenience Economies - The emotional economy is highlighted through the success of brands like "Labubu" and "Rio," which cater to consumers' desires for comfort and enjoyment during challenging times [28][29][30]. - The convenience economy is on the rise, with frozen food brands and smart home appliances addressing the needs of younger generations who have less time for cooking [33][35][36]. Group 5: Strategic Planning and Future Outlook - The article concludes by urging businesses to adapt their strategies in light of these emerging trends, emphasizing the importance of strategic planning and resource allocation to thrive in a low-desire economy [39][40].

Group 1 - The core point of the article is the announcement by Jinbo Bio regarding the change in its sponsoring representative due to the work shift of the previous representative, Yao Yao [2] - CITIC Securities has appointed Zhong Shan to replace Yao Yao as the sponsoring representative for the company's ongoing supervision and the stock issuance project for specific targets in 2025 [2] - The ongoing supervision sponsoring representatives have been changed to Deng Jun and Zhong Shan [2]

关于变更向不特定合格投资者公开发行股票并在北京证券交易所上市 持续督导、2025年度向特定对象发行股票保荐代表人的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 法律责任。 山西锦波生物医药股份有限公司（以下简称"公司"）于2025年12月12日收到 保荐机构中信证券股份有限公司（以下简称"中信证券"）《关于更换保荐代表人 的函》，具体情况如下： 证券代码：920982 证券简称：锦波生物 公告编号：2025-183 山西锦波生物医药股份有限公司 中信证券作为公司向不特定合格投资者公开发行股票并在北京证券交易所上市 项目及2025年度向特定对象发行股票项目的保荐机构，其中，鉴于向不特定合格投 资者公开发行股票并在北京证券交易所上市项目处于法定持续督导期间，保荐机构 尚需履行持续督导义务，持续督导保荐代表人为邓俊、姚曜；2025年度向特定对象 发行股票项目的保荐代表人为邓俊、姚曜。现因原保荐代表人姚曜工作变动原因， 不再负责公司持续督导工作及本次向特定对象发行股票的保荐工作。为保证公司持 续督导工作及本次向特定 ...

Trading Volume and Market Activity - On December 12, the total trading volume of individual stocks on the Beijing Stock Exchange reached 1.134 billion shares, with a total transaction value of 26.973 billion yuan, a decrease of 1.332 billion yuan compared to the previous trading day [1] - Among the tradable stocks, 143 stocks closed higher, accounting for 50% of the total, while 139 stocks closed lower [1] - The stocks with the highest closing gains included Chuangyuan Xinke, Changfu Co., and Caneng Electric Power, which rose by 14.80%, 11.38%, and 11.29% respectively [1] Stock Performance Highlights - The stocks with the highest transaction values included Jinbo Biological, Xingtou Measurement Control, and Tianli Composite, with transaction values of 1.045 billion yuan, 869 million yuan, and 862 million yuan respectively [1] - A total of 76 stocks had transaction values exceeding 10 million yuan, indicating significant trading activity [1] - The highest turnover rates were observed in stocks such as Dapeng Industrial, Jingchuang Electric, and Guangdao Tui, with turnover rates of 70.76%, 45.80%, and 41.72% respectively [1] Price Movements - The stock Guangdao Tui experienced the largest decline, dropping by 21.09%, followed by Longzhu Technology and Henghe Co., which fell by 6.56% and 6.53% respectively [1] - The closing prices of notable stocks included Jinbo Biological at 275.50 yuan, Tianli Composite at 60.84 yuan, and Chuangyuan Xinke at 31.80 yuan [1][2]

证券时报·数据宝统计显示，锦波生物今日收盘价为275.50元，上涨9.02%，日换手率为7.01%，成交额 为10.40亿元，近5日该股累计上涨20.67%。 据天眼查APP显示，山西锦波生物医药股份有限公司成立于2008年03月28日，注册资本11506.534万人 民币。（数据宝） 锦波生物（920982）12月12日大宗交易平台出现一笔成交，成交量1.46万股，成交金额478.88万元，大 宗交易成交价为328.00元，相对今日收盘价溢价19.06%。该笔交易的买方营业部为中信证券股份有限公 司大连高新园区证券营业部，卖方营业部为华泰证券股份有限公司南京长江路证券营业部。 进一步统计，近1个月内该股累计发生6笔大宗交易，合计成交金额为3240.88万元。 | 成交量 | 成交金额 | 成交价格 | 相对当日收 盘价折溢价 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | （%） | | | | 1.46 | 478.88 | 328.00 | 19.06 | 中信证券股份有限公司 大连高新园区证券营 ...

Core Viewpoint - The A-share market shows positive momentum with the Shanghai Composite Index closing above the annual line, indicating a potential bullish trend in the market [1] Group 1: Market Performance - As of 13:59 today, the Shanghai Composite Index stands at 3888.05 points, with a change of 0.38% [1] - The total trading volume of A-shares today reached 1,628.31 billion yuan [1] Group 2: Stocks Breaking Annual Line - A total of 135 A-shares have surpassed the annual line today, with notable stocks including Jiusheng Electric, Shifeng Culture, and Xilong Science, which have deviation rates of 10.24%, 6.95%, and 6.26% respectively [1] - Stocks with smaller deviation rates that have just crossed the annual line include Xiying Technology, Sifang Technology, and Yuyue Medical [1] Group 3: Deviation Rate Rankings - The top three stocks with the highest deviation rates are: - Jiusheng Electric (11.21% increase, latest price 19.44 yuan, deviation rate 10.24%) [1] - Shifeng Culture (9.99% increase, latest price 21.79 yuan, deviation rate 6.95%) [1] - Xilong Science (10.00% increase, latest price 9.35 yuan, deviation rate 6.26%) [1] - Other notable stocks with significant increases include Tiandi Digital (8.20% increase) and Yunlu Co. (6.11% increase) [1]